安普贴联合喜疗妥对化疗患者静脉炎的预防及对hs-CRP和IL-6的影响  

Algoplaque combined with hirudoid for the prevention of phlebitis in patients receiving chemotherapy and the effects on hs-CRP and IL-6

作　　者：金一青[1] 黄李华[1] 

机构地区：[1]上海市同济大学附属肺科医院肿瘤4病房,上海200433

出　　处：《中国肿瘤临床与康复》2017年第6期722-725,共4页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨安普贴联合喜疗妥预防化疗患者静脉炎的效果及对患者血清高敏C-反应蛋白(hs-CRP)和白细胞介素-6(IL-6)水平的影响。方法选取2015年9月至2016年9月间上海市同济大学附属肺科医院收治的400例接受化疗的恶性肿瘤患者,采用随机数字表法分为观察组与对照组,每组200例。患者均行常规静脉化疗,对照组患者化疗时在穿刺点上方贴安普贴治疗,观察组患者在对照组基础上沿穿刺静脉走向涂喜辽妥治疗。比较两组患者静脉炎的发生情况、疼痛情况、治疗前后的肝肾功能及血清hs-CRP和IL-6水平的变化情况。结果治疗1周后,观察组患者静脉炎发生情况明显优于对照组(0.5%vs 3.5%),组间比较,差异有统计学意义(P<0.05);两组患者疼痛情况比较(0.0%vs 28.6%),差异无统计学意义(P>0.05)。两组患者治疗后血清hs-CRP(10.35±3.18 vs 13.27±4.25;10.59±3.46 vs 16.30±5.51)和IL-6(5.24±2.17 vs 8.66±2.53;5.57±2.39 vs 11.82±3.77)水平较治疗前均上升,且对照组患者上升更为显著,差异均有统计学意义(均P<0.05)。两组患者治疗前后肝肾功能指标均未发生明显变化,差异均无统计学意义(均P>0.05)。结论恶性肿瘤化疗患者采用安普贴联合喜疗妥预防治疗,能够有效减少静脉炎的发生,且不会影响肝肾功能,有一定的临床价值。Objective To investigate the efficacy of algoplaque combined with hirudoid for the prevention of phlebitis in patients receiving chemotherapy and the effects on serum high sensitivity CRP（hsCRP） and interleukin-6（IL-6）. Methods Four hundred patients with malignant tumors receiving chemotherapy were selected at Shangha Pulmonary Hospital Affiliated to Tongji University from September 2015 to September 2016 and using a random number table,patients were divided into the an observation group and a control group with 200 patients in each group. All the patients were treated with conventional intravenous chemotherapy. Patients in the observation group were treated with algoplaque combined with hirudoid and patients in the control group were treated with algoplaque. Incidence of phlebitis,pain and changes of the liver and kidney function and serum hs-CRP and IL-6 were compare between the two groups. Results At 1week after the treatment,the incidence of phlebitis was significantly lower in the observation group than in the control group（0. 5% vs 3. 5%）（P〈0. 05）. There was no significant difference in pain between the two groups（0. 0% vs 28. 6%）（P〉0. 05）. After treatment,hs-CRP（10. 35 ± 3. 18 vs 13. 27 ± 4. 25;10. 59 ± 3. 46 vs 16. 30 ± 5. 51） and IL-6（5. 24 ± 2. 17 vs 8. 66 ± 2. 53; 5. 57 ± 2. 39 vs 11. 82 ± 3. 77）significantly increased in both groups than before the treatment and the control group got more significant increase（all P〈0. 05）. The indicators of liver and kidney function did not change significantly in both groups before and after treatment. Conclusion The combination of algoplaque and hirudoid for the prevention of phlebitis in patients receiving chemotherapy can effectively reduce the incidence of phlebitis without affecting the liver and kidney function,which makes it have a certain clinical value.

关 键 词：安普贴 喜疗妥 药物疗法 静脉炎 

分 类 号：R473.73[医药卫生—护理学]